Akt activation is common in progressive thyroid cancer. In breast cancer, Akt1 induces primary cancer growth, but is reported to inhibit metastasis in vivo in several model systems. In contrast, clinical and in vitro studies suggest a metastasis-promoting role for Akt1 in thyroid cancer. The goal of this study was to determine the functional role of Akt1 in thyroid cancer growth and metastatic progression in vivo using thyroid hormone receptor (TR) b PV/PV knock-in (PV) mice, which develop metastatic thyroid cancer. We crossed Akt1
Akt activation is common in progressive thyroid cancer. In breast cancer, Akt1 induces primary cancer growth, but is reported to inhibit metastasis in vivo in several model systems. In contrast, clinical and in vitro studies suggest a metastasis-promoting role for Akt1 in thyroid cancer. The goal of this study was to determine the functional role of Akt1 in thyroid cancer growth and metastatic progression in vivo using thyroid hormone receptor (TR) b PV/PV knock-in (PV) mice, which develop metastatic thyroid cancer. We crossed Akt1
À/À and PV mice and compared tumor development, local progression, metastasis and histology in TRb 
/Akt1
À/À (PVPV-Akt1KO) mice. Mice were killed at 3, 6, 9, 12 and 15 months; necropsy was performed and serum thyroid stimulating hormone (TSH) was measured. Thyroid hyperplasia occurred in both groups beginning at 3 months; the thyroid size was greater in the PVPVAkt1WT mice (Po0.001). In comparison with PVPVAkt1WT mice, thyroid cancer development was delayed in the PVPV-Akt1KO mice (P ¼ 0.003) and the degree of tumor invasiveness was reduced. The PVPV-Akt1WT mice displayed pulmonary metastases at 12 and 15 months of age, by contrast PVPV-Akt1KO mice did not develop distant metastases at 15 months of age. Despite continued expression of Akt2 or Akt3, pAkt levels were decreased and there was evidence of reduced Akt effect on p27 in the PVPV-Akt1KO thyroids. TSH levels were similarly elevated in PV mice regardless of Akt1 expression. In conclusion, thyroid cancer development and progression in TR b
Introduction
Akt (protein kinase B) represents a family of three proteins, Akt1, 2 and 3, encoded by unique genes with sequence and functional similarities. Akt family members regulate diverse cell functions including proliferation, apoptosis, motility and glucose uptake and utilization. It has been recognized increasingly that the Akt isoforms have similar, but not entirely overlapping functions (reviewed in (Stambolic and Woodgett, 2006) ). Determinants of Akt isoform-specific activity may relate to affinity for specific intracellular chaperones, subcellular localization, availability for phosphatase interactions, or tissue or cell-type specific functions. For example, altered subcellular localization was recently demonstrated to be critical for the specific role of Akt2 in insulin sensitivity in adipocytes (Gonzalez and McGraw, 2009) , and Akt2 loss in mice causes a phenotype with type 2 diabetes (Cho et al., 2001a) , whereas Akt1 loss causes small size, but no evidence of diabetes (Chen et al., 2001) . When considering cell motility and invasion, in some cell systems, Akt1 enhances cell invasion and migration, whereas in other systems, it inhibits migration and invasion and Akt2 has a pro-motility function (Dillon and Muller, 2010) . These differences in vitro may be a function of the cell type being studied or other specific details of the model systems. The data have been extended to in vivo models in breast cancer, in which Akt1 loss inhibits primary tumor growth, but results in increased metastatic progression in several models consistent with a potential metastasis inhibiting role (Hutchinson et al., 2004; Irie et al., 2005; Yoeli-Lerner et al., 2005; Liu et al., 2006; Cheng et al., 2007; Dillon et al., 2009) . Interestingly, in this system, loss of Akt2 inhibits metastatic progression. These data suggest that isoform-specific inhibition of Akt may be needed for therapeutic targeting in breast cancer. Whether these results are applicable to other solid tumors is uncertain.
Akt1 is reported to have a pro-motility role in thyroid cancer, colon cancer and melanoma cells in vitro (Vasko et al., 2004; Saji et al., 2005) . Moreover, Akt1 null fibroblasts are relatively less motile and invasive than control fibroblasts Zhou et al., 2006) , raising the possibility that Akt1 effects on motility are cell type specific. In human thyroid carcinoma tissue samples, an increase in phosphorylated Akt is common in the invasive fronts in a manner that co-localizes with Akt1, but not Akt2 or 3 (Vasko et al., 2004) . Moreover, mutations in the pleckstrin homology domain of Akt1, but not Akt2 or 3, have been identified in metastatic thyroid cancer tissue from patients with recurrence that does not respond to standard therapies (Ricarte-Filho et al., 2009) . These data suggest that Akt1 may have an important role in promoting thyroid cancer progression.
In animal models, Akt activation induced by loss of expression of phosphate and tensin homolog located on chromosome 10, either in all tissues or just in the thyroid, leads to goiter formation and in some cases, minimally invasive thyroid cancer (Podsypanina et al., 1999; Di Cristofano et al., 2001) . Tumor formation is reduced by crossing the mice into an Akt1 deficient background (Chen et al., 2006) . However, the impact of Akt isoforms on metastases could not be assessed using this system and most endogenous in vivo thyroid cancer models develop metastases only after the tumors are anaplastic (Kim and Zhu, 2009) . One model of thyroid cancer in which mice develop metastatic thyroid cancer with differentiated features is the thyroid hormone receptor (TR) b PV/PV knock-in (PV) model (Suzuki et al., 2002) . In this model, mice homozygous for a knock-in of the PV mutation of TRb develop thyroid hormone resistance, high thyroid stimulating hormone (TSH) levels and metastatic thyroid cancer that maintains differentiated features. Although the TSH levels are supraphysiological, this model allows for identification of pathways involved in differentiated thyroid cancer metastatic progression. We previously reported that similar to human thyroid cancer, increased activation of Akt occurred in the primary tumor and distant metastatic tissues from these mice, and that Akt1 colocalized with pAkt in the primary tumors (Kim et al., 2005) . In vitro studies using primary cultured thyrocytes from the tumors demonstrated Akt-dependent invasiveness (Kim et al., 2005) . Mechanistic studies demonstrate that the TRbPV has a high affinity for the regulatory domain of PI3K, even when not bound to T3, thereby causing constitutive PI3K signaling (Furuya et al., 2006) . In vivo, the tumor progression is dependent on PI3K activity based on pharmacological studies and to a lesser degree on mammalian target of rapamycin, using a TORC1 complex inhibitor (Guigon et al., 2010) ; however, Akt isoform specificity has not been assessed.
The goal of the present study was to determine if TRbPV thyroid cancer development and progression were dependent on Akt1. Our results demonstrate that loss of Akt1 reduced both tumor formation and metastatic progression. This effect occurred without Akt1-related changes in TSH levels. These data demonstrate that Akt1 has both tumor proliferative and prometastatic functions in the TRbPV model system, similar to both correlative studies in human cancers and functional studies in vitro.
Results
Deletion of Akt1 reduces thyroid enlargement in the TRbPVPV mice TRb PV/PV /Akt1
(PVPV-Akt1WT) mice developed goiters beginning at 3 months of age. Thyroid enlargement was also noted in the TRb PV/PV /Akt1 À/À (PVPVAkt1KO) mice, but it was less dramatic than in the presence of Akt1 (examples shown Figure 1a ). This was also identified using ultrasound (Supplementary Figure 1) . Statistically, when normalized for body weight, the increase in thyroid size in PVPV mice was delayed by Akt1 deletion (Figure 1b , Po0.001). Over time, similar body weight-normalized thyroid sizes were achieved. This was felt, in part, to be due to an increase in the death of the PVPV-Akt1WT mice, with the largest Akt1 and thyroid cancer development and progression in vivo M Saji et al goiters due to compression of local structures, as the metastatic burden was very small. Consistent with this speculation, the rate of spontaneous death was greater in the PVPV-Akt1WT (32%) compared with the PVPV-Akt1KO (19%) mice, although the study was not designed to evaluate spontaneous death rate as an end point.
Thyroid stimulating hormone levels are not changed by loss of Akt1 PVPV mice have high TSH levels due to their thyroid hormone resistance (Kaneshige et al., 2000) . To assess whether differences in the thyroid histology or tumor behavior correlated with a change in circulating TSH levels, serum TSH was measured at 9, 12 and 15 months of age. PVPV-Akt1WT and -Akt1KO mice had similar TSH levels, and both were statistically greater than levels in the wild type (WT) and homozygous Akt1 null (Akt1KO) littermate control mice (Figure 2 , Po0.001).
The lack of effect of Akt1 loss on TSH levels is further supported by comparable levels in the WT and Akt1KO control mice. Consistent with the TSH levels, there was no difference in pituitary size or in the incidence of basophil hyperplasia by histology in the presence or absence of Akt1 in the PVPV mice. In both cases, the pituitaries were markedly larger than littermate controls (Supplementary Figure 2A) .
Deletion of Akt1 delays tumor progression, vascular invasion, and distant metastases in PVPV mice
Histological examination revealed that B75% of the PVPV-Akt1WT mice developed thyroid carcinomas at 6 months of age (Figures 3a and 4a), whereas PVPVAkt1KO mice showed only adenomas. At 9 months of age, all PVPV-AktWT mice, but only 2/7 PVPVAkt1KO, had thyroid carcinomas ( Figure 3 ). The deletion of Akt1 significantly delayed the formation of thyroid carcinoma (P ¼ 0.003). Although both PVPVAkt1WT and -Akt1KO mice developed thyroid carcinomas after 12 months, the histological findings differed between the two groups. Carcinomas in PVPV-Akt1WT
Figure 2 TSH levels are not affected by loss of Akt1. TSH levels were assessed at 9, 12 and 15 months (M) of age in WT, Akt1 KO (KO), PVPV-Akt1WT (PV) and PVPV-Akt1KO (PVKO) mice. TSH levels in the WT and KO were similar. Levels in the PV and PVKO mice were both markedly elevated vs the WT and KO mice (Po0.001) and were statistically similar to each other in all age groups. In contrast, the majority of the PVPV-Akt1KO mice had adenomas at 9 months ( Figure 4f ). When carcinomas developed in these mice, only minimal capsular invasion was identified and the tumors maintained a follicular morphology (Figures 4g and h ). Vascular invasion in thyroid carcinomas from the PVPV-Akt1KO mice was rare (only one mouse) even at 15 months (Figures 4g  and h ). Tumor associated macrophages were not identified by immunostaining in thyroid tissues from either genotype. Thyroglobulin mRNA levels were slightly lower and thyroid transcription factor 1 mRNA levels were similar in the PVPV-Akt1WT and PVPVAkt1KO mice by quantitative reverse-transcription PCR (RT-PCR) (PVPV-Akt1KO/PVPV-Akt1WT ratio 0.655 ± 0.144 and 1.309 ± 0.438, respectively). Distant metastases to the lungs were only observed in PVPV-Akt1WT (Figures 3b and 4e ) at 12 and 15 months of age, thus metastases began to occur between 9 and 12 months. In contrast, no PVPV-Akt1KO mice had detectable distant metastases, up to 15 months of age, even after serial sectioning. On the basis of significant incidence difference above, we used a directional (single-sided test) for metastasis and this difference was significant (P ¼ 0.04). Together, these data demonstrate that Akt1 promotes both tumor growth and progression in the PVPV mice.
Akt2 and 3 do not compensate for the loss of Akt activity in Akt1 in PVPV thyroid carcinomas Because of the potential for compensatory overexpression and activation of Akt2 and 3 in the thyroid cancers in the PVPV-Akt1KO mice, we examined gene and protein expression of Akt1, Akt2 and Akt3 by real-time RT-PCR, immunohistochemistry (IHC) and western blot. Akt1 mRNA and protein were not detectable in the Akt1KO and PVPV-Akt1KO mice. Akt2 and 3 mRNA levels were not significantly different between WT and PVPV-Akt1WT in thyroid tissues at the mRNA level; although Akt2 level tended to be higher in the Akt1KO mice. Similar results were obtained in the pituitary gland at the mRNA level (Table 1) and protein levels on IHC (Supplementary Figure 2B) .
IHC of the thyroid revealed Akt1, 2 and 3 immunoactivity in the PVPV-WT thyroid carcinomas and WT controls. IHC also demonstrated loss of Akt1 in the thyroid tissue with no convincing evidence of compensatory enhanced expression of Akt2 or Akt3 in the absence of Akt1, although there was some evidence of an increase in Akt2 localization to the nucleus, in the absence of Akt1 (Figure 5a ). Interestingly, despite retained expression of Akt2 and 3, immunoactive pAkt levels were markedly reduced in the absence of Akt1 in the thyroid carcinomas (Figure 5b ), suggesting that Akt2 and 3 were not able to compensate for loss of Akt1 function in the thyroid carcinomas. Western blot confirmed the loss of Akt1, the absence of compensatory overexpression of Akt2 and 3 and the lower levels of phosphorylated Akt in the thyroid tumors (Supplementary Figure 3) . Akt1 and thyroid cancer development and progression in vivo M Saji et al p27 Kip1 and gelsolin are regulated by Akt1 in PVPV thyroid carcinomas Akt phosphorylates p27 leading to its cytosolic sequestration (Fujita et al., 2002; Liang et al., 2002; Shin et al., 2002; Viglietto et al., 2002) . This effect has been demonstrated to be important for Akt pro-motility effects in vitro (Saji et al., 2005; Wu et al., 2006) .
We therefore assessed expression levels and localization of p27 in the thyroid cancers. In comparison to PVPV-Akt1WT mice that had cytosolic-predominant p27 immunoactivity, the PVPV-Akt1KO mice demonstrated nuclear-predominant p27, consistent with loss of Akt function despite continued expression of Akt 2 and 3 (Figure 5b) . Moreover, expression of gelsolin, a Akt1 and thyroid cancer development and progression in vivo M Saji et al stabilizer of actin that is activated by phosphoinositides (Chellaiah et al., 2001) , is markedly reduced in the PVPV-Akt1WT mice at the mRNA and protein levels and its re-expression reduces PVPV thyroid cancer cell invasiveness in vitro (Kim et al., 2007) . To determine if Akt1 regulated gelsolin levels in vivo, we assessed gelsolin IHC and demonstrated that protein levels were restored in PVPV-Akt1KO (Figure 5b ). Taken together with the loss of pAkt immunoactivity, these results are consistent with the loss of Akt function in the thyroid tumors in the PVPV-Akt1KO mice.
Discussion
The three Akt proteins exhibit structural and functional similarities and together function to increase glucose utilization, promote cell growth, regulate cell motility and inhibit apoptosis. Opposing Akt1 isoform-specific functions on cell motility, invasion and metastatic tumor progression have been reported in breast cancer models (Irie et al., 2005; He´ron-Milhavet et al., 2006; Liu et al., 2006; Dillon and Muller, 2010) . In addition, Akt2 has been shown to be a key stimulator of neutrophil migration (Chen et al., 2010) . These observations are particularly important, given the development of both generalized and isoform specific Akt inhibitors for clinical trials. Earlier work in thyroid cancer cells, cancer cells from other organs, vascular endothelial cells and fibroblasts, have identified a pro-motility function for Akt1 in vitro Meng et al., 2006; Zhou et al., 2006; Fernandez-Hernando et al., 2009 ). These differences could be related to the specific cell lines and assays or they might represent tissue-specific responses to Akt isoforms.
In the present study, we report that Akt1 deletion delays thyroid cancer formation in the PVPV mouse model and reduces vascular invasion and distant metastases over 15 months in vivo. The loss of Akt1 was associated with a marked reduction in immunoreactive phosphorylated Akt in the tumors, despite continued expression of Akt2 and 3. The relocalization of p27 to the nucleus provides further evidence for the loss of total Akt activation in thyroid cancer tissues. It is not clear why loss of Akt1 is not rescued by Akt2 or 3 in the thyroid; however, the data are consistent with those from phosphate and tensin homolog located on chromosome 10 null mice in which 80% of mice with a Pten þ /À genotype develop thyroid tumors, whereas only 43% develop tumors when they lack Akt1 (Chen et al., 2006) . In the same study, prostate cancer incidences in both groups were similar, supporting the notion of tissue specific effects of the Akt isoforms.
TSH levels are elevated in the TRb PV mouse model (Figure 2 and Suzuki et al., 2002) . TSH is a major growth factor for thyroid cells (reviewed in Kimura et al., 2001 ) that cooperates with Akt signaling in inducing cell proliferation (Coulonval et al., 2000; Saito et al., 2001 ). The effect of Akt1 deletion in the thyroid carcinomas occurred, despite similar TSH levels in the PVPV-Akt1WT and PVPV-Akt1KO. Thus, it is not likely that changes in TSH alone are responsible for the results. However, the Akt1 effects in the thyroid may still require increased TSH receptor signaling. Indeed, TSH receptor signaling has been shown to have an important growth promoting role in thyroid cancer in the PV mouse model, but it is not sufficient to induce thyroid cancer in the mouse . This may account for the difference between the thyroid and pituitary changes, because pituitary tissue does not express the TSH receptor. Thus, in this model system, co-activation of TSH receptors and other signaling pathways are required for the aggressive phenotype to develop. The principal advantage of this model for the present study is the reliable development of pulmonary micrometastases that retain differentiated features; however, it is also recognized that the very high TSH levels and the PV mutation in the TRb receptor are not typical in human thyroid cancer.
The mechanisms by which Akt1 loss reduces thyroid cancer metastasis in this model are not certain and were not directly tested in this study. It is possible that novel interacting proteins may exist for Akt and TRb in the mice. This possibility was not tested in the present manuscript. However, two potential mechanisms were explored on the basis of earlier functional studies. We previously reported that Akt-induced cell motility is dependent on p27 expression in vitro . Akt is known to phosphorylate p27 at several locations, leading to its cytosolic sequestration and ability to bind to actin filaments (Fujita et al., 2002; Liang et al., 2002; Shin et al., 2002; Viglietto et al., 2002; McAllister et al., 2003; Wu et al., 2006; Larrea et al., 2009 ). In the PV mouse thyroid cancers, we demonstrate that increased levels of nuclear pAkt and cytoplasmic-predominant p27 are consistent with Akt activation. In the absence of Akt1, pAkt levels were reduced and p27 relocalized to the nucleus, consistent with loss of Akt function. Gelsolin is a phosphoinositide-regulated protein involved in capping of actin filaments that reduces cell motility (Chellaiah et al., 2001; Tanaka et al., 2006) . Loss of gelsolin expression is associated with aggressive tumor behavior or tumor development and its reexpression reduces cancer cell invasiveness and mesenchymal features (Mielnicki et al., 1999; Tanaka et al., 2006; Ni et al., 2008) . Previously published microarray studies demonstrated a reduction of gelsolin mRNA levels in PVPV tumors (Ying et al., 2003) . Furthermore, primary cultures of PVPV thyroid cancer cell invasion requires loss of gelsolin (Kim et al., 2007) . Therefore, we were interested in determining whether loss of Akt1 altered gelsolin levels in the tumors. Indeed the PVPV-Akt1KO thyroid tumors displayed markedly increased levels of gelsolin ( Figure 5 ). The role of Akt1 in regulating gelsolin transcription, translation or protein stability requires further study.
It is possible that distant metastases will be identified as the mice continue to age, and that the reduction in distant metastases is related directly to the delay in primary tumor progression. The low frequency of vascular invasion Akt1 and thyroid cancer development and progression in vivo M Saji et al and the absence of distant metastases even 3-6 months after the cancers developed in the PVPV-Akt1KO mice suggest that Akt1 has an effect on the metastatic process; however, this has not been directly proven. Nonetheless, it is important to recognize that in contrast to breast cancer, the results do not support a metastasis-suppressing role for Akt1 in the PVPV model of thyroid cancer. It is also important to recognize that we have utilized a generalized Akt1 null system and the genetic background is not pure C57BL/6J. Thus, while we have identified effects of Akt1 loss in the thyroid cancer cells, Akt1 is also deleted in other tissues that can impact on cancer progression. As with all mouse models, there also may be strain-specific modifier effects. Indeed, recent data demonstrate that activation of Akt signaling in the stroma can independently influence the behavior of breast cancer in mice (Trimboli et al., 2009) . These noncancer cell or strain-specific effects may also influence the apparent tissue specificity of the Akt1 effects.
In summary, we have demonstrated for the first time that thyroid cancer development, vascular invasion and distant metastases in the TRb PV mouse model are dependent on Akt1. These Akt1 isoform-specific effects occur with similarly high TSH levels, in the presence of Akt2 and 3, and in association with changes in p27 localization and gelsolin expression. These results demonstrate that Akt1 functions to promote tumor development and progression in the PVPV model of thyroid cancer.
Materials and methods

Mice
Akt1
þ /À mice on a C57BL/6J background were obtained from Jackson Laboratory (#004912, Bar Harbor, MI, USA) (Cho et al., 2001b) and homozygous Akt1 knockout (Akt1 À/À ) mice were generated. The homozygous Akt1 À/À mice were mated with heterozygous TRbPV (TRb PV/À ) on a C57BL/6Jx129SV (Kaneshige et al., 2000) to create homozygous TRbPV (TRb . For genotyping, crude DNA was isolated from tail biopsies and PCR was performed using previously described methods and primers (Kaneshige et al., 2000; Cho et al., 2001b) . Mice were killed at 3, 6, 9, 12 and 15 months of age and the thyroid, lung, pituitary and liver tissues were harvested and fixed with 10% formalin and stored in À80 freezer until protein and RNA were isolated. Body weight and thyroid size were measured at necropsy. Thyroid volume was calculated by the following formula: (Volume) ¼ (Longest length) Â (Shortest length) 2 Â 0.52. Mouse studies were approved by the Ohio State University Institutional Animal Care and Use Committee.
Antibodies
Antibodies against total Akt (#9272), H40 and GAPDH (#2118) were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies against phosphorylated (Ser 473)-Akt (sc-7985-R), Akt3 (sc-11520), gelsolin (sc-48769) and a-tubulin (sc-5546) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody against GAPDH (NB300-327) was from NOVUS Biologicals (Littleton, CO, USA). Antibody against Akt1 (#610860) and p27(Kip1) (#554069) were from BD Biosciences (Billerica, MA, USA). Antibody against Akt2 (#06-606) was from Upstate Biotechnology (Lake Placid, NY, USA). Anti-CD34 was from Abcam (Cambridge, MA, USA) and anti F4/80 was from Invitrogen (Carlsbad, CA, USA). Specificity of isoformspecific anti-Akt antibodies was previously confirmed (Vasko et al., 2004; Saji et al., 2005) . Secondary antibodies against rabbit and mouse were from Cell Signaling and against sheep, from Upstate Biotechnology.
Histology and immunohistochemistry
Thyroid, lung and pituitary tissues were fixed in 10% zinc formalin (Fisher Scientific, Pittsburgh, PA, USA) for 3 days, processed by routine methods, embedded in paraffin and 4-mm-sections were made. Hematoxylin and eosin stained slides were evaluated by light microscopy by one veterinary pathologist (KLP). When metastases were not identified in lung tissues, an additional 10 sections from different depths were cut and subjected to hematoxylin and eosin staining. For IHC, sections were dewaxed and soaked in alcohol. After microwave treatment in antigen unmasking solution (Vector Laboratory, Burlingame, CA, USA) for 10 min, endogenous peroxidase activity was inactivated by incubating in 3% hydrogen peroxide for 15 min and sections were incubated with primary antibody in phosphate-buffered saline at 4 1C overnight. After washing with phosphate-buffered saline, immunostaining was performed using the Vectastain Universal Quick Kit and DAB Peroxidase Substrate Kit (Vector Laboratories, Burlingame, CA, USA) according to the manufacturer's instructions. Antiserum was omitted in the negative control. hematoxylin and eosin staining and IHC were reviewed by at least three investigators including KLP, MS, MDR and VVV; IHC results were interpreted independently and consensus was obtained if qualitative interpretations differed.
TSH measurement
Blood was harvested at necropsy and serum was collected after centrifugation of blood at 3000 Â g for 15 min and stored at À80 1C until the assay was performed. As higher levels of TSH were expected in PVPV mice (Kaneshige et al., 2000) , serum was diluted with TSH-free mouse serum . Serum TSH levels were determined as described (Pohlenz et al., 1999) .
RNA isolation and analysis
Half of the thyroid tissue from each mouse and the entire pituitary gland from randomly selected mice were stored at À80 1C. Tissues were homogenized in 1 ml of Trizol (Invitrogen) and after addition of 200 ml of chloroform, tubes were shaken, incubated for 2 min at room temperature and centrifuged at 16 000 g for 15 min at 4 1C. The supernatant was mixed with 500 ml of isopropanol, and centrifuged at 16 000 g for 15 min at 4 1C. The supernatant was aspirated and the pellets containing RNA were washed using 70% ethanol and air-dried. The RNA was then reconstituted in diethylpyrocarbonate-treated water and concentration was measured by spectrophotometry (230/260/280).
For RT-PCR, 880 ng of RNA were treated with DNase I (Invitrogen) for 15 min and 400 ng of DNase-treated RNA were reversed transcribed using the TaqMan Reverse Transcription Reagents Kit (Applied Biosystems). Quantitative PCR was performed in 96 sample plates, using cDNA equivalent to 24 ng of total RNA (3 ml of RT reaction mixture) per 20 ml per well. As an internal control to normalize gene expression, 18S ribosomal RNA was amplified using Taqman Ribosomal RNA Control Reagents Kit as described (Ringel et al., 2001) . Specific primers for Akt1 were the following: forward 5 0 -AGCTCTTCTTCCACCTGTCTC-3 0 (Exon 7-8) and reverse 3 0 -CGGCGTTCCGCAGAATGT-5 0 (Exon 9). Specific primers and probes for Akt2 (Mm00545827_m1), Akt3 (Mm00442194_m1), thyroglobulin (Mm00447525_m1), TTF-1 (Mm00657018_m1) and gelsolin (Mm00456679_m1 were purchased from Applied Biosystems and PCR was performed with SYBR Green Mix (Applied Biosystems) for Akt1 and TaqMan Universal PCR Master Mix (Applied Biosystems) for other genes using the following parameters: after an initial 2 min incubation at 50 1C for inactivation of AmpEASE Uracil-NGlycosylase activity, the cDNA was denatured at 94 1C for 10 min and samples were subjected to 40 cycles of a two-step amplification protocol that included 15 s at 94 1C and a 1-min annealing-elongation step at 60 1C. Target gene and 18S were amplified in all samples in duplicate in two separate reactions. Negative controls were included for the RT (RT negative) and PCR (non-template control) reactions. To compare expression levels, difference of threshold (DCt) were calculated by subtracting threshold (Ct-18S) of 18S from threshold (Ct-gene) of the target gene and expression levels were estimated by 2 (ÀDCt) . All samples were electrophoresed to confirm the sizes of the amplicons and reaction specificity.
Statistical analysis
Thyroid volume, adjusted for body weight and TSH levels, were assessed by linear models to estimate and test differences due to the presence or absence of Akt1. The primary hypothesis was that Akt1 loss would inhibit tumor formation. The effect of Akt1 on tumor formation at fixed ages was assessed using logistic regression modeling. To assess subsequent effects of Akt1 on the development of distant metastases, logistic regression was performed beginning at 12 months of age, as that was the age at which distant metastases were expected in the PVPV mice. Significance tests were performed at the a ¼ 0.05 level (double-sided) for the primary endpoints of thyroid size and incidence of tumor formation. The number of mice used for each of the age groups provided 83% power to detect an effect size of Akt1 on tumor incidence consistent with the earlier studies that demonstrated complete penetrance of thyroid cancer formation in the PVPV mice by 9 months of age (Suzuki et al., 2002) and the anticipated reduction in tumor formation with Akt1 loss (Chen et al., 2006) . Power for thyroid tumor volume as a continuous indicator of growth was much higher. Finally, significance testing for distant metastases was one-sided, because its direction depended on the results from the test of incidence. For the logistic regression modeling, exact tests were used to accommodate the small sample sizes and the potential for zero events.
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